Anti-androgens in the treatment of prostate cancer and risk of secondary cancers: Overview of non clinical models and regulatory perspectives

被引：0
|
作者：
Belhouari, H. [1 ]
Vidil, F. [1 ]
Louin, G. [1 ]
Burbank, M. [1 ]
Richard, A. [1 ]
Salomon, V. [1 ]
机构：
[1] ANSM, DMS, St Denis, France
来源：
TOXICOLOGY LETTERS | 2021年 / 350卷
关键词：
D O I：
暂无
中图分类号：
R99 [毒物学（毒理学）];
学科分类号：
100405 ;
摘要：
P13-20
引用
收藏
页码：S156 / S157
页数：2
相关论文
共 22 条
  • [11] Second generation anti-androgens and androgen deprivation therapy with radiation therapy in the definitive management of high-risk prostate cancer
    Wang, Edina C.
    Lee, W. Robert
    Armstrong, Andrew J.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2023, 26 (01) : 30 - 40
  • [12] Review of HPLC and LC-MS/MS assays for the determination of various nonsteroidal anti-androgens used in the treatment of prostate cancer
    Suresh, P. S.
    Srinivas, Nuggehally R.
    Mullangi, Ramesh
    BIOMEDICAL CHROMATOGRAPHY, 2018, 32 (01)
  • [13] Risk of Fatigue and Anemia in Patients With Prostate Cancer Treated With Novel Oral Anti-androgens: A Meta-Analysis of Randomized Controlled Trials
    Babkoor, Abdulrahman A.
    Aljabri, Yazeed
    Alzubaidi, Ahmad
    Alhazmi, Rayan
    Alsaedi, Zeyad
    Alghamdi, Faris
    Tamim, Tariq
    Aldagani, Ahmad
    Seddiqi, Irfan
    Tashkandi, Emad
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (01)
  • [14] Efficacy and Safety of Non-Steroidal Anti-Androgens in Patients with Metastatic Prostate Cancer: Meta-Analsis of Randomized Controlled Trials
    Rashid, Muhammed
    Ramesh, Madhan
    Shamshavali, K.
    Dang, Amit
    Patel, Himanshu
    Undela, Krishna
    REVIEWS ON RECENT CLINICAL TRIALS, 2020, 15 (01) : 34 - 47
  • [15] Predictors of poor response to first-generation anti-androgens as criteria for alternate treatments for patients with non-metastatic castration-resistant prostate cancer
    Kenichiro Fukuoka
    Jun Teishima
    Hirotaka Nagamatsu
    Shogo Inoue
    Tetsutaro Hayashi
    Koji Mita
    Masanobu Shigeta
    Kanao Kobayashi
    Mitsuru Kajiwara
    Yuichi Kadonishi
    Takatoshi Tacho
    Akio Matsubara
    International Urology and Nephrology, 2020, 52 : 77 - 85
  • [16] Predictors of poor response to first-generation anti-androgens as criteria for alternate treatments for patients with non-metastatic castration-resistant prostate cancer
    Fukuoka, Kenichiro
    Teishima, Jun
    Nagamatsu, Hirotaka
    Inoue, Shogo
    Hayashi, Tetsutaro
    Mita, Koji
    Shigeta, Masanobu
    Kobayashi, Kanao
    Kajiwara, Mitsuru
    Kadonishi, Yuichi
    Tacho, Takatoshi
    Matsubara, Akio
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2020, 52 (01) : 77 - 85
  • [17] Gonadotropin-releasing hormone agonists, anti-androgens and the risk of cardio-cerebrovascular disease in prostate cancer patients: an asian population-based observational study
    Seong, Jong-Mi
    Shin, Dongho
    Sung, Jae Woo
    Cho, Shinjay
    Yang, Jonghyup
    Kang, Sungmin
    Moon, Hyong Woo
    Lee, Kyu Won
    Ha, U-Syn
    JOURNAL OF CANCER, 2020, 11 (14): : 4015 - 4022
  • [18] Will the Addition of Second Generation Anti-Androgens in Addition to Standard Androgen-Deprivation Therapy and Radiotherapy be Cost-Effective in the Treatment of Node Positive Prostate Cancer: A Cost-Effectiveness Analysis
    Konski, A. A.
    Chen, R. C.
    Havrilesky, L.
    Sartor, O.
    Efstathiou, J. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E440 - E440
  • [19] Racial variations in COVID-19 deaths may be due to androgen receptor genetic variants associated with prostate cancer and androgenetic alopecia. Are anti-androgens a potential treatment for COVID-19?
    McCoy, John
    Wambier, Carlos G.
    Vano-Galvan, Sergio
    Shapiro, Jerry
    Sinclair, Rodney
    Ramos, Paulo Muller
    Washenik, Kenneth
    Andrade, Murilo
    Herrera, Sabina
    Goren, Andy
    JOURNAL OF COSMETIC DERMATOLOGY, 2020, 19 (07) : 1542 - 1543
  • [20] Anti-CCR4 treatment depletes regulatory T cells and leads to clinical activity in a canine model of advanced prostate cancer
    Maeda, Shingo
    Motegi, Tomoki
    Iio, Aki
    Kaji, Kenjiro
    Goto-Koshino, Yuko
    Eto, Shotaro
    Ikeda, Namiko
    Nakagawa, Takayuki
    Nishimura, Ryohei
    Yonezawa, Tomohiro
    Momoi, Yasuyuki
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (02)
123